No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): Subsidiary has received the approval notification for the drug clinical trial.
On December 25, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries, Shanghai Shengdi Pharmaceuticals Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd., received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration for injectable SHR-4602, injectable SHR-A1811, adebrelimab injection, and SHR-8068 injection, and will soon initiate clinical trials.
Hengrui Medicine Subsidiaries Receive Approval for Anti-Tumor Drug Trial
Jiangsu Hengrui Pharmaceuticals (600276.SH): The injection SHR-1681 has received the drug clinical trial approval notification.
On December 20, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries, Shanghai Shengdi Pharmaceutical Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd., received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the injectable SHR-1681, and clinical trials will begin soon. The injectable SHR-1681 is a Class I therapeutic Biological Product independently developed by the company, which can specifically bind to certain antigens on the surface of tumor cells, and then be endocytosed into the cells and transported to lysosomes to kill tumor cells.
Jiangsu Hengrui Medicine Gets China Green Light for Bladder Cancer Drug Combo
Hengrui Medicine's Unit Included In Chinese Drug Administration's Breakthrough Therapy Drug List
Jiangsu Hengrui Pharmaceuticals (600276.SH): Injection Rycan-Cumab has been included in the proposed list of breakthrough treatment varieties.
On December 16, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Co., Ltd., has had its injectable recombinant trastuzumab (SHR-A1811) included in the proposed list of breakthrough therapy varieties by the National Medical Products Administration's Drug Review Center, with a publication period of 7 days. In addition, this product has already received breakthrough therapy designation for six indications. The injectable recombinant trastuzumab can bind to and be internalized by HER2-expressing tumor cells, releasing toxins via proteolytic cleavage in the tumor cell lysosome, inducing cell cycle arrest and subsequently inducing apoptosis in tumor cells.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
No Data
